CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
|Slideshows|October 3, 2019
Fysh debuts fall collection of linear and lightweight designs
Author(s)Alex Delaney-Gesing, Senior Editor
Advertisement
Thin, linear designs and lightweight constructions define the Fysh collection for Fall 2019. With patterns and contemporary color combinations, these new styles feature an unconventional play with shapes.
Advertisement
Related to this article
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin IL-6 receptor inhibitor approved in the indication.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
More than monitoring: Using AMD visits to promote healthy vision aging
4
The Independent Advantage S02 E07: Is your front desk missing opportunities?
5